Mallinckrodt (MNK) wins IPR decisions on INOMax blood-vessel drug - Bloomberg

Leerink Boosts PT on Mallinckrodt (MNK) to $92; Lifts INOMax Expectations

Leerink is lifting its price target on Outperform-rated Mallinckrodt (Nasdaq: MNK) from $91 up to $92 following recent estimate adjustments.

The firm commented Friday: We're publishing our updated model to reflect MNK's nuclear imaging divestiture, which is dilutive to EPS but accretive to the growth profile of the company. We are also increasing our INOMax (respiratory) forecasts based on our analysis following encouraging feedback from two MEDACorp neonatology specialists ... we assessed the commercial prospects for MNKs INOMax franchise, which has beaten consensus expectations in the last 4 qtrs by 8-11%.... More

Drug Stocks on Watch as Bipartisian Bill Expected on Capping Price Increases

Pharmaceutical stocks are on watch Thursday amid reports a bipartisan bill to cap drug price increases will be introduced in both on the House and Senate. The bill is expected to require drug makers to notify the Department of HHS if a price increase of 10% or more is planned.... More

pSivida (PSDV) Makes Leadership Changes, Including New CEO Appointment

pSivida Corp. (Nasdaq: PSDV) announced that its Board of Directors has appointed Nancy Lurker as its President and Chief Executive Officer and a member of the Board of Directors. Ms. Lurker, a seasoned healthcare executive, brings strong leadership and extensive experience in maximizing the potential of new therapies and successfully implementing innovative U.S. and global drug launches. Paul Ashton, PhD, who has been pSividas President and Chief Executive Officer for many years, has resigned to pursue other interests.

We are delighted to welcome Nancy Lurker to... More